Genmab A/S (GMAB) Reports Q3 Net DARZALEX Sales of $2.5B

Genmab A/S (Nasdaq: GMAB) announced today that worldwide net trade sales of DARZALEX® (daratumumab), including sales of the subcutaneous (SC) product (daratumumab and hyaluronidase-fihj, sold under the tradename DARZALEX FASPRO® in the U.S.), as reported by Johnson & Johnson were USD 2,499 million in the third quarter of 2023. Net trade sales were USD 1,369 million in the U.S. and USD 1,130 million in the rest of the world. Genmab receives royalties on the worldwide net sales of DARZALEX, both the intravenous and SC products, under the exclusive worldwide license to Janssen to develop, manufacture and commercialize daratumumab.

You May Also Be Interested In

• Genmab Announces Financial Results for the First Half of 2026
• Construction Partners, Inc. (ROAD) Tops Q3 EPS by 1c ; Offers Guidance
• Docebo Inc. (DCBO) Tops Q2 EPS by 5c ; Offers Guidance